Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Caterpillar Inc. (NYSE:CAT). In a filing ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

So, you want to invest in AbbVie (NYSE: ABBV) because it's a promising dividend-paying stock, and you also want to receive $1 ...

AbbVie’s stock dipped 0.29% to close at $213.85, a minor move compared to the S&P 500's steeper 1.07% drop. Despite this ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie closed at $213.85 after slipping 0.29%, yet it outperformed the S&P 500’s 1.07% drop. Despite a recent dip, the stock ...

AbbVie (ABBV) closed the most recent trading day at $213.85, moving -0.29% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. At the same time, ...

Bearish flow noted in AbbVie (ABBV) with 6,427 puts trading, or 1.5x expected. Most active are 4/11 weekly 210 puts and Mar-25 190 calls, with ...

Forget the old adage “it takes money to make money.” In the stock market, even a measly $500 can kickstart a fortune. Time, not a fat wallet, is the real MVP here. With the right picks, that modest ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits ...